Use RX adds 2 biosimilars Stelara to the form to help patients save costs

Serve you RX, a pharmacy service manager, added two biosimilars recently approved in Stelara to its form, the company announced on Thursday.

Milwaukee, based in Wisconsin, you RX service is an independent PBM serving insurance brokers, consultants, third -party administrators and their employers.

The two biosimilars he added to his form are OLTFI and Yesintek, who are used to treat patients for Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis. A biosimilar is a drug which is very similar in the structure and function of a brand biological medicine, but which is much cheaper. Stelara costs around $ 20,000 a month, according to you to serve the CEO of RX Justin Jasnietski, but the company will be able to help customers save around 96% with Oltulfi and around 90% with Yesintek.

Traditionally, PBMS will always cover the brand medication even if the low -cost biosimilars are available, which led patients to pay much more than necessary. But serving you RX does things differently.

“One of the things we have done is that we have created a new form specific to us, called the Biosimillaar Advantage form that excludes reference products at high cost,” said Jasnietski in an interview. “And it essentially forces that patients must first take biosimilars at a lower cost, because it is like taking a generic drug for the most part, they are essentially clinically identical.”

Otulfi will be distributed exclusively through Mark Cuban Cost plus the pharmaceutical company (more medication cost). Cost Plus Drugs is a prescription medication company which removes pharmacy intermediaries and negotiates directly with drug manufacturers to obtain cheaper prices.

Yesintek will be offered on the specialized pharmacy network of your RX, which is powered by Waltz Health. Waltz Health offers a market called Waltz Connect, where specialized pharmacies are competing on quality, clinical results and prices. In April, companies announced a partnership that gives you RX Access customers to Waltz Connect. When a specialty prescription is subject to a member, the platform redirects it to the most appropriate pharmacy according to the design of the advantages, the price, the recovery time, the precision of realization, the experience of the members and the membership rate of the members.

Companies plan to extend to more biosimilars in the future, noted Mark Thierer, co-founder and CEO of Waltz Health.

“This biosimilar announcement is actually only the start,” he said in an interview. “You will see Waltz feed this smart routing for many high-cost specialized drugs. And we are waiting for Justin and our other customers will use it for Cancer’s care for GLP-1. It is a very long list, and there is a mountain of money to be saved in collapse the supply chain and by facilitating patients to access these drugs.”

Goodrx has also launched initiatives for biosimilars. For example, he teamed up with Boehringer Ingelheim last year to provide his humilia biosimilar for an exclusive cash price of $ 550 per two packs.

Photo: Cagkansayin, Getty Images